TY - JOUR
T1 - The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis
T2 - A consensus statement from the North American Imaging in Multiple Sclerosis Cooperative
AU - Sati, Pascal
AU - Oh, Jiwon
AU - Todd Constable, R.
AU - Evangelou, Nikos
AU - Guttmann, Charles R.G.
AU - Henry, Roland G.
AU - Klawiter, Eric C.
AU - Mainero, Caterina
AU - Massacesi, Luca
AU - McFarland, Henry
AU - Nelson, Flavia
AU - Ontaneda, Daniel
AU - Rauscher, Alexander
AU - Rooney, William D.
AU - Samaraweera, Amal P.R.
AU - Shinohara, Russell T.
AU - Sobel, Raymond A.
AU - Solomon, Andrew J.
AU - Treaba, Constantina A.
AU - Wuerfel, Jens
AU - Zivadinov, Robert
AU - Sicotte, Nancy L.
AU - Pelletier, Daniel
AU - Reich, Daniel S.
N1 - Publisher Copyright:
© 016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.
AB - Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.
UR - https://www.scopus.com/pages/publications/84994718072
U2 - 10.1038/nrneurol.2016.166
DO - 10.1038/nrneurol.2016.166
M3 - Article
C2 - 27834394
AN - SCOPUS:84994718072
SN - 1759-4758
VL - 12
SP - 714
EP - 722
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 12
ER -